Univest
Univest
  • Markets

SYMBIOTEC PHARMALAB (SYMBIOTEC) Share Price hits fresh 52-week high as stock trades at Rs 1,262.90

  • September 10, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
SYMBIOTEC Share Price
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) share price reached a fresh 52-week high of Rs 1,269.3 today and later stood at Rs 1,262.9, up 7.65% from the previous close. Market cap was Rs 7,077.17 crore.

SYMBIOTEC Share Price is in focus after SYMBIOTEC PHARMALAB LTD touched a fresh 52-week high of Rs 1,269.30 and was trading at Rs 1,262.90, up Rs 89.75 or 7.65%, at 14 October 2026 at 11:52 AM IST. The company’s market cap stood at Rs 7,077.17 crore, placing SYMBIOTEC Share Price among the notable healthcare names in current market action. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. For readers following SYMBIOTEC Share Price Today, the move also keeps SYMBIOTEC Stock News, SYMBIOTEC Share News and SYMBIOTEC Latest News firmly in view.

What happened today is straightforward: SYMBIOTEC Share Price moved from the previous close of Rs 1,173.15 to intraday highs and a current level above Rs 1,260. The opening price matched the previous close, and the day’s low also remained at Rs 1,173.15, while the day’s high matched the fresh 52-week high. That makes SYMBIOTEC Share Price a clear one-year high event rather than a broader claim about record levels. The stock’s current move is relevant because the latest Univest figures combine a fresh price high with valuation metrics, sector context and peer comparisons that help frame SYMBIOTEC Share Price analysis.

Table of Contents

Toggle
  • SYMBIOTEC Share Price Today: Price Action Analysis
  • SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching SYMBIOTEC PHARMALAB LTD
  • About SYMBIOTEC PHARMALAB LTD
  • Frequently Asked Questions
    • What is the current SYMBIOTEC Share Price?
    • Did SYMBIOTEC Share Price hit a fresh 52-week high?
    • What is the market cap linked to SYMBIOTEC Share Price?
    • How does SYMBIOTEC Share Price compare on valuation?
    • What are the ROE and ROCE for SYMBIOTEC Share Price analysis?
    • What EPS and book value support SYMBIOTEC Share Price?
    • Is SYMBIOTEC Share Price paying a dividend?
    • How does SYMBIOTEC Share Price compare with peers?
  • Track SYMBIOTEC Share Price on Univest

SYMBIOTEC Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 1,262.9
Previous Close Rs 1,173.15
Today's Move +Rs 89.75 (+7.65%)
Open Rs 1,173.15
High Rs 1,269.3
Low Rs 1,173.15
Market Capitalisation Rs 7,077.17 crore

For investors tracking SYMBIOTEC Share Price Live, the key question is not only where the stock traded today, but what the verified financial context looks like. The latest Univest figures show a P/E ratio of 68.59, P/B ratio of 5.03, ROE of 11.22%, ROCE of 12.41%, EPS of 17.1 and book value of Rs 233.38. Dividend yield is 0.00. That combination keeps SYMBIOTEC Share Price in valuation focus alongside the fresh 52-week high.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) traded at Rs 1,262.9 versus the previous close of Rs 1,173.15, a rise of 7.65%. The stock opened at Rs 1,173.15, reached a high of Rs 1,269.3 and touched a low of Rs 1,173.15.

SYMBIOTEC Share Price Today shows a strong intraday move built on a simple starting point: the stock opened at Rs 1,173.15, exactly where the previous close stood, and then advanced to a high of Rs 1,269.30. The current price of Rs 1,262.90 leaves SYMBIOTEC Share Price Rs 89.75 above the previous close, equal to a 7.65% rise. The low for the day also stayed at Rs 1,173.15, which means the stock moved from the opening level to the fresh 52-week high in the same session. That is the core price action story behind SYMBIOTEC Share Price today.

For SYMBIOTEC Share Price analysis, the session matters because the current quote sits only slightly below the day’s high of Rs 1,269.30. The fresh 52-week high is therefore not a distant reference point; it is the top level reached in the current move. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. That leaves SYMBIOTEC Share Price reading as a verified market event, not a narrative built on unverified drivers.

In stock analysis terms, the price action is clean and numerically clear. SYMBIOTEC Share Price Today shows an upward step from the previous close, a high that equals the fresh 52-week high, and a current level that remains near that intraday peak. For readers comparing SYMBIOTEC Share Price News across the day, those are the only price facts that need emphasis before moving to valuation and fundamentals.

The next useful step is valuation. SYMBIOTEC Share Price is now best read alongside the company’s financial profile, since the move to a yearly high comes while the market is also pricing in its earnings, book value and return ratios.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis

Metric Value
Market Capitalisation Rs 7,077.17 crore
P/E Ratio 68.59x
P/B Ratio 5.03x
ROE 11.22%
ROCE 12.41%
EPS Rs 17.1
Book Value Per Share Rs 233.38
Dividend Yield 0%

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 68.59x, P/B 5.03x, ROE 11.22%, ROCE 12.41%. Read together, these ratios describe the company’s position rather than a recommendation.

SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 7,077.17 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 68.59x, P/B at 5.03x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.48x, median ROE of 11.69%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 68.59x
Benchmark Median P/E 31.48x
Benchmark Average P/E 46.61x
Benchmark P/E Range 3.11x to 663.29x
Company P/B Ratio 5.03x
Benchmark Median P/B 2.91x
Company ROE 11.22%
Benchmark Median ROE 11.69%
Company ROCE 12.41%
Benchmark Median ROCE 13.61%
Company Market Capitalisation Rs 7,077.17 crore
Benchmark Median Market Cap Rs 819.72 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 68.59x, which is above the benchmark median of 31.48x, a difference of +117.88%. The P/E comparison frames valuation; it is not a signal to buy or sell.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.69%, a difference of -4.02%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.61%, a difference of -8.82%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Supriya Lifescience Ltd. SUPRIYA 7,105.83 35.82 5.82 19.06 25.3
Morepen Laboratories Ltd. MOREPENLAB 7,008.33 47.49 5.12 7.96 10.19
Bliss GVS Pharma Ltd. BLISSGVS 7,153.38 52.4 5.79 12.11 17.4
Sanofi India Ltd. SANOFI 6,753.5 21.06 8.26 44.5 55.46
Aarti Pharmalabs Ltd. AARTIPHARM 7,962.59 37.63 3.66 8.5 10.77

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 68.59x compared with the displayed peer median of 37.63x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 11.22% compares with a peer median of 12.11% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 17.4%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 7,077.17 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching SYMBIOTEC PHARMALAB LTD

  • SYMBIOTEC Share Price touched a fresh 52-week high of Rs 1,269.30 and was trading at Rs 1,262.90.
  • The day move in SYMBIOTEC Share Price was Rs 89.75, or 7.65%, versus the previous close of Rs 1,173.15.
  • SYMBIOTEC Share Price shows a P/E ratio of 68.59 and a P/B ratio of 5.03.
  • ROE for SYMBIOTEC Share Price is 11.22% and ROCE is 12.41%.
  • SYMBIOTEC Share Price has a market cap of Rs 7,077.17 crore and Jun 2026 revenue of Rs 218.15 crore.

About SYMBIOTEC PHARMALAB LTD

SYMBIOTEC PHARMALAB LTD operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. SYMBIOTEC Share Price is therefore linked to a business classified within a large listed healthcare universe. The latest Univest figures place the company inside a same-industry benchmark set of 198 companies and a broader sector group of 286 companies. That industry and sector classification is the main verified company context available for SYMBIOTEC Share Price today.

For readers scanning SYMBIOTEC Share Price and company overview content together, the core facts are straightforward: the company name, sector, industry, market cap and key valuation ratios are all visible in the current market data set. SYMBIOTEC Share Price can be tracked alongside those numbers rather than any unsupported operational narrative.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

What is the current SYMBIOTEC Share Price?

Ans. SYMBIOTEC Share Price was trading at Rs 1,262.90 when the article was prepared. The stock had moved up Rs 89.75, or 7.65%, from the previous close of Rs 1,173.15.

Did SYMBIOTEC Share Price hit a fresh 52-week high?

Ans. Yes. SYMBIOTEC Share Price touched a fresh 52-week high of Rs 1,269.30 during the session. The current quote remained close to that level, keeping the yearly high event in focus.

What is the market cap linked to SYMBIOTEC Share Price?

Ans. The market capitalisation associated with SYMBIOTEC Share Price is Rs 7,077.17 crore. That places the company above the same-industry market cap median and below the same-industry average. The stock moved 7.65% so far today.

How does SYMBIOTEC Share Price compare on valuation?

Ans. SYMBIOTEC Share Price shows a P/E ratio of 68.59 and a P/B ratio of 5.03. Both sit above the same-industry medians, which makes valuation an important part of the current discussion.

What are the ROE and ROCE for SYMBIOTEC Share Price analysis?

Ans. SYMBIOTEC Share Price has ROE of 11.22% and ROCE of 12.41%. ROE is slightly below the same-industry median, while ROCE is also below the same-industry median. The stock moved 7.65% so far today.

What EPS and book value support SYMBIOTEC Share Price?

Ans. SYMBIOTEC Share Price is supported by EPS of 17.1 and book value of Rs 233.38. EPS reflects earnings per share, while book value shows the accounting net worth per share.

Is SYMBIOTEC Share Price paying a dividend?

Ans. The dividend yield shown for SYMBIOTEC Share Price is 0.00. That means the current figures do not show a dividend yield contribution, so the focus remains on price and valuation ratios.

How does SYMBIOTEC Share Price compare with peers?

Ans. SYMBIOTEC Share Price sits within the peer market-cap band shown in the comparison set. Its P/E is higher than most peers listed, while ROE and ROCE sit below some stronger return profiles in the group.

Track SYMBIOTEC Share Price on Univest

Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Users can track SYMBIOTEC Share Price on Univest for live price updates, 52-week levels, market cap, valuation ratios and healthcare sector context. SYMBIOTEC Share Price, SYMBIOTEC Fundamental Analysis and SYMBIOTEC Stock Analysis are all easier to review when the price, benchmark and peer numbers are kept together in one place.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply